IP Verse

Use Of A Vegf Antagonist To Treat Angiogenic Eye Disorders

EP3716992

REGENERON PHARMACEUTICALS, INC.
Application Number
EP18825837A
Filing Date
Nov 29, 2018
Status
Granted And Under Opposition
Jul 8, 2022
Grant Date
Aug 10, 2022
External Links
Slate, Register

Biblio Summary

The patent EP3716992B1 was granted on Aug 10, 2022 by Regeneron Pharmaceuticals, Inc. The patent is currently Granted And Under Opposition.

Oppositions Filed by other Companies on the Patent

The table below shows 4 patent oppositions filed on the patent at EPO, listing each opposing company and filing date. Tracking these filings indicates that the applicant is active in this industry, while opposing companies may be signaling their own interest in competing within the same space. These disputes are essential for insights into competitor actions, patent strategy and emerging technological trends.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

AMGENMay 10, 2023ADMISSIBLE
MAIWALD GMBHMay 10, 2023ADMISSIBLE
BOULT WADE TENNANT LLPMay 9, 2023ADMISSIBLE
WUESTHOFF & WUESTHOFF PATENTANWALTE PARTG MBBMay 5, 2023ADMISSIBLE

More Opposed Patents of Regeneron Pharmaceuticals, Inc.

The table below shows the patents of Regeneron Pharmaceuticals, Inc. that have been opposed by other companies.

Patent NumberTitleGrant DateOpposition Count
EP3110848Methods For Treating Skin Infection By Administering An Il-4R AntagonistFeb 14, 20245
EP3515465Methods For Treating Severe Atopic Dermatitis By Administering An Il-4R InhibitorFeb 7, 20247
EP3973987Methods For Treating Or Preventing Asthma By Administering An Il-4R AntagonistJan 10, 20246

Dossier Documents of the Patent

The documents dossier of the patent at EPO including all essential records in the patent's lifecycle, from filing to grant to oppositions.

  • Date

    Description

  • Get instant alerts for new documents